DNLI Denali Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: DNLI

Price (delayed)

$20.46

Market cap

$3.27B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.84

Enterprise value

$3.3B

?
Relative Growth: Rel. Growth: 5
Relative Strength: Rel. Strength: 61
Relative Valuation: Rel. Valuation: 1
Relative Profitability: Rel. Profitability: 27
Highlights
The quick ratio has declined by 20% year-on-year and by 12% since the previous quarter
Denali Therapeutics's equity has decreased by 19% YoY and by 10% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://www.denalitherapeutics.com
Peers: NVAX NVCR NBIX

Key stats

What are the main financial stats of DNLI

DNLI stock price

How has the Denali Therapeutics stock price performed over time
Intraday
-5.28%
1 week
1.99%
1 month
-17.9%
1 year
56.78%
YTD
23.92%
QTD
-20.45%

Financial performance

How have Denali Therapeutics's revenue and profit performed over time
Revenue
$3.6M
Gross profit
$3.51M
Operating income
-$542.7M
Net income
-$511.45M
Gross margin
97.4%
Net margin
-14,191.2%
The net income is down by 7% year-on-year

Price vs fundamentals

How does DNLI's price correlate with its fundamentals

Growth

What is Denali Therapeutics's growth rate over time

Valuation

What is Denali Therapeutics stock price valuation
P/E
N/A
P/B
3.89
P/S
1,063.39
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
916.1
DNLI's price to book (P/B) is 28% more than its last 4 quarters average of 3.2 and 24% more than its 5-year quarterly average of 3.3
Denali Therapeutics's equity has decreased by 19% YoY and by 10% QoQ

Efficiency

How efficient is Denali Therapeutics business performance
The return on equity has declined by 36% year-on-year and by 6% since the previous quarter
The return on invested capital has declined by 29% year-on-year
The return on assets has declined by 21% year-on-year

Dividends

What is DNLI's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for DNLI.

Financial health

How did Denali Therapeutics financials performed over time
DNLI's total liabilities has surged by 132% year-on-year but it is down by 5% since the previous quarter
The quick ratio has declined by 20% year-on-year and by 12% since the previous quarter
Denali Therapeutics's debt is 72% less than its equity
Denali Therapeutics's equity has decreased by 19% YoY and by 10% QoQ
DNLI's debt to equity is up by 12% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.